TickerTalks
Browse all tickers →
TickerTalks›$TRAX
TRTRAX

First Tracks Biotherapeutics Inc

$TRAX·$1.6B·Biotechnology·Healthcare
$43.11+2.9%1Y+126.9%
Mentions · last 7 days
2026-08-17: 1 posts2026-08-18: 5 posts2026-08-19: 0 posts2026-08-20: 1 posts2026-08-21: 2 posts2026-08-22: 2 posts2026-08-23: 1 posts12+13%
Price updated 2d ago·X counts updated 8h ago
TRTRAX
$TRAXFirst Tracks Biotherapeutics Inc
$43.11+2.89%12 posts+13%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $TRAX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventEvent coming upAI verdict · as of 2026-08-22

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Immunology spinout up 127% over twelve months on read-through from a Forte Biosciences vitiligo readout; the pipeline dates are what matters next.

First Tracks Biotherapeutics is a newly-spun San Diego immunology company advancing rosnilimab, ANB033 and ANB101 through clinical stages. The tape is up 127% over twelve months on a mix of clinical read-through and analyst upgrades, and the setup is now waiting on the specific dates.

  • Q2 EPS was -$0.95 versus a -$0.74 estimate for a 28% miss, and Q1 EPS of -$1.45 with $32.6M in free-cash-flow burn reflects a real Phase-2/3 spend profile against consensus that has no near-term revenue expectations.
  • The August 3-week tape drove a +40% move on read-through from Forte Biosciences ($FBRX) Phase 1b vitiligo results validating the CD122 pathway — a legitimate mechanism-adjacency signal, though X trader chatter of sales at $50 and re-entry at $40 suggests the volatility profile matches early-stage biotech more than a de-risked catalyst play.
  • August 13 analyst forecast increases following Q2 results plus the July 17 Moderate Buy consensus rating anchor the sell-side story; three Form 3/A filings on August 7 flag ownership housekeeping without substantive open-market activity in the bundle.

Next scheduled earnings date is not yet in the bundle; the operative catalysts remain rosnilimab, ANB033 and ANB101 clinical progression rather than a specific print date.

Agrees with X sentimentX's mixed short-timeframe framing on the Forte read-through, the +40% move, and the tactical sell-and-rebuy sequence matches the tape; the LEGN-Carvykti-royalty comparison is directional rather than a bundle-verifiable event.

What to watch: Next earnings date once scheduled, rosnilimab clinical readouts, and any ANB033 or ANB101 program updates.

On the calendar: Q3 earnings (not yet scheduled)

float missingbeta missing

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment6 posts analyzed · as of 2026-08-03

Small, tactical window. TRAX ran +40% to new highs with no visible news, attributed to read-through from Forte Biosciences ($FBRX) Phase 1b vitiligo results validating the CD122 pathway. One trader sold his full position at $50, then re-bought a 30% starter at $40. Another set a hard stop citing tech-sector contagion fears. Discussion around $LEGN spinning out Carvykti royalty like $ANAB did for TRAX. Mixed positioning; no dominant directional view.

Read the AI verdict + X sentiment for $TRAX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage immunology company developing T-cell-modulating antibodies for autoimmune and inflammatory diseases, including rosnilimab and ANB033.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $TRAX.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $TRAX

Neutral — Clinical-stage immunology company developing T-cell-modulating antibodies for autoimmune and inflammatory diseases, including rosnilimab and ANB033; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+52.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-11.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-40.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-6.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-30.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 12, 2026$-0.95$-0.74-28.4%

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-1.45$-32.6M
Q1 FY25$0———$-1.36$-45.0M

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+30.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β3.375-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 1 other (1 other) in window

See when $TRAX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3/ANew insider — initial holdingsAug 73/A
3/ANew insider — initial holdingsAug 73/A
3/ANew insider — initial holdingsAug 73/A
8-KMaterial agreementJun 228-K — Item 1.01: Material agreement
AI summary

First Tracks Biotherapeutics, Inc. entered into a Sublease Agreement with AnaptysBio, Inc. on June 15, 2026 for approximately 45,057 rentable square feet of lab/office space at 10770 Wateridge Circle, San Diego, CA, for an initial 12-month term (with an extension option to April 4, 2028 and a 3-month early termination right). Rent equals the monthly Basic Rent plus Additional Rent owed by AnaptysBio under its master lease, plus company-requested service charges. Operationally material for the clinical-stage biotech — establishes its primary facility footprint in a major biotech hub; the short initial term with extension optionality provides flexibility.

S-1Initial registrationMay 8S-1
3New insider — initial holdingsApr 233
3New insider — initial holdingsApr 223
3New insider — initial holdingsApr 223
+ 30 other (9 3s · 6 13Gs · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Resultsbenzinga.com·11d agoFirst Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updateglobenewswire.com·12d agoFirst Tracks Biotherapeutics (NASDAQ:TRAX) Receives Consensus Rating of “Moderate Buy” from Analystsdefenseworld.net·38d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$CAPR$IOVA$NWBO$SLS$ABCL
Voices on X · last 7 days

No standout posts about $TRAX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport